Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease
Lenora Higginbotham,Lingyan Ping,Eric B. Dammer,Duc M. Duong,Maotian Zhou,Marla Gearing,Cheyenne Hurst,Jonathan D. Glass,Stewart A. Factor,Erik C. B. Johnson,Ihab Hajjar,James J. Lah,Allan I. Levey,Nicholas T. Seyfried +13 more
TLDR
Results are a promising step toward a network-based biomarker tool for AD clinical applications and identify cerebrospinal fluid biomarkers representing a wide spectrum of AD pathophysiology.Abstract:
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) biomarkers representing a wide spectrum of AD pathophysiology. Multiplex mass spectrometry identified ~3500 and ~12,000 proteins in AD CSF and brain, respectively. Network analysis of the brain proteome resolved 44 biologically diverse modules, 15 of which overlapped with the CSF proteome. CSF AD markers in these overlapping modules were collapsed into five protein panels representing distinct pathophysiological processes. Synaptic and metabolic panels were decreased in AD brain but increased in CSF, while glial-enriched myelination and immunity panels were increased in brain and CSF. The consistency and disease specificity of panel changes were confirmed in >500 additional CSF samples. These panels also identified biological subpopulations within asymptomatic AD. Overall, these results are a promising step toward a network-based biomarker tool for AD clinical applications.read more
Citations
More filters
Journal ArticleDOI
Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains.
Tamta Arakhamia,Christina E. Lee,Yari Carlomagno,Duc M. Duong,Sean R. Kundinger,Kevin Wang,Dewight Williams,Michael DeTure,Dennis W. Dickson,Casey Cook,Nicholas T. Seyfried,Leonard Petrucelli,Anthony W. P. Fitzpatrick +12 more
TL;DR: Cryo-electron microscopy is used to determine the structures of tau filaments from corticobasal degeneration (CBD) human brain tissue and proposes a structure-based model in which cross-talk between PTMs influences tau filament structure, contributing to the structural diversity of tauopathy strains.
Journal ArticleDOI
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics
Betty M. Tijms,Johan Gobom,Johan Gobom,Lianne M. Reus,Iris E. Jansen,Shengjun Hong,Valerija Dobricic,Fabian Kilpert,Mara ten Kate,Frederik Barkhof,Magda Tsolaki,Frans R.J. Verhey,Julius Popp,Julius Popp,Pablo Martinez-Lage,Rik Vandenberghe,Alberto Lleó,José Luis Molinuevo,Sebastiaan Engelborghs,Sebastiaan Engelborghs,Lars Bertram,Simon Lovestone,Simon Lovestone,Johannes Streffer,Stephanie J.B. Vos,Isabelle Bos,Isabelle Bos,Kaj Blennow,Kaj Blennow,Philip Scheltens,Charlotte E. Teunissen,Henrik Zetterberg,Pieter Jelle Visser,Pieter Jelle Visser,Pieter Jelle Visser +34 more
TL;DR: In this article, the dual clustering technique non-negative matrix factorization was used to detect Alzheimer's disease biological subtypes in CSF proteomics using the dual-clustering technique.
Journal ArticleDOI
Artificial intelligence for proteomics and biomarker discovery
TL;DR: In this paper, the authors focus on mass spectrometry (MS)-based proteomics and describe how machine learning and, in particular, deep learning now predicts experimental peptide measurements from amino acid sequences alone.
Journal ArticleDOI
Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease.
Lingyan Ping,Sean R. Kundinger,Duc M. Duong,Luming Yin,Marla Gearing,James J. Lah,Allan I. Levey,Nicholas T. Seyfried +7 more
TL;DR: An unbiased multiplex quantitative proteomic and phosphoproteomic analysis using tandem mass tag isobaric labeling of human post-mortem cortex across pathology-free controls, AsymAD and symptomatic AD individuals is reported.
Journal ArticleDOI
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Sruti Rayaprolu,Lenora Higginbotham,Pritha Bagchi,Caroline M. Watson,Tian Zhang,Allan I. Levey,Srikant Rangaraju,Nicholas T. Seyfried +7 more
TL;DR: How network-based proteomics has emerged as a powerful tool and how its application to the AD brain has provided an informative framework for the complex protein pathophysiology underlying the disease is described.
References
More filters
Journal ArticleDOI
WGCNA: an R package for weighted correlation network analysis.
Peter Langfelder,Steve Horvath +1 more
TL;DR: The WGCNA R software package is a comprehensive collection of R functions for performing various aspects of weighted correlation network analysis that includes functions for network construction, module detection, gene selection, calculations of topological properties, data simulation, visualization, and interfacing with external software.
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Suzanne S. Mirra,Albert Heyman,Daniel W. McKeel,S. M. Sumi,Barbara J. Crain,L. M. Brownlee,Vogel Fs,James P. Hughes,van Belle G,Leonard Berg +9 more
TL;DR: The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects, which provides neuropathologic definitions of such terms as “definite Alzheimer's disease” (AD), “probable AD,” “possible AD” and “normal brain” to indicate levels of diagnostic certainty.
Related Papers (5)
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
Erik C. B. Johnson,Eric B. Dammer,Duc M. Duong,Lingyan Ping,Maotian Zhou,Luming Yin,Lenora Higginbotham,Andrew Guajardo,Bartholomew White,Juan C. Troncoso,Madhav Thambisetty,Thomas J. Montine,Edward B. Lee,John Q. Trojanowski,Thomas G. Beach,Eric M. Reiman,Vahram Haroutunian,Vahram Haroutunian,Minghui Wang,Eric E. Schadt,Bin Zhang,Dennis W. Dickson,Nilufer Ertekin-Taner,Todd E. Golde,Vladislav A. Petyuk,Philip L. De Jager,David A. Bennett,Thomas S. Wingo,Srikant Rangaraju,Ihab Hajjar,Joshua M. Shulman,James J. Lah,Allan I. Levey,Nicholas T. Seyfried +33 more
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease
Nicholas T. Seyfried,Eric B. Dammer,Vivek Swarup,Divya Nandakumar,Duc M. Duong,Luming Yin,Qiudong Deng,Tram Nguyen,Chadwick M. Hales,Thomas S. Wingo,Thomas S. Wingo,Jonathan D. Glass,Marla Gearing,Madhav Thambisetty,Madhav Thambisetty,Juan C. Troncoso,Daniel H. Geschwind,James J. Lah,Allan I. Levey +18 more
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more